Evaluating Botulinum Toxin for Upper Limb Spasticity After Stroke
Author Information
Author(s): Helen Rodgers, Lisa Shaw, Christopher Price, Frederike van Wijck, Michael Barnes, Laura Graham, Gary Ford, Phil Shackley, Nick Steen
Primary Institution: Institute for Ageing and Health, Newcastle University
Hypothesis
The study aims to evaluate the clinical and cost effectiveness of botulinum toxin type A plus an upper limb therapy programme in treating post-stroke upper limb spasticity.
Conclusion
The study will assess whether combining botulinum toxin with therapy improves upper limb function in stroke patients.
Supporting Evidence
- Upper limb spasticity affects 55-75% of stroke patients long-term.
- Botulinum toxin is increasingly used to treat focal spasticity.
- Effective management of spasticity requires a multidisciplinary approach.
Takeaway
This study is trying to find out if a special medicine called botulinum toxin can help people who have trouble moving their arms after a stroke, especially when used with therapy.
Methodology
A multi-centre open-label parallel group randomised controlled trial comparing botulinum toxin type A plus upper limb therapy with upper limb therapy alone.
Potential Biases
Potential selection bias as participants were recruited from specialized centers rather than general stroke services.
Limitations
The study may not fully represent all stroke patients due to the exclusion of those with significant cognitive impairments.
Participant Demographics
Adults with upper limb spasticity due to stroke, aged over 18 years, with a stroke occurring more than 1 month prior.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website